Introduction {#s1}
============

The correct formation and subsequent maintenance of synapses is a key prerequisite for brain development, function and longevity. Precocious loss of synapses is observed in late onset neurodegenerative diseases including Alzheimer\'s disease (AD) and Frontotemporal Dementia (FTD), likely contributing to the cognitive decline and neuronal decay observed in patients ([@bib42]; [@bib51]; [@bib54]). Therefore, the characterisation of mechanisms maintaining synapses during ageing would have major implications for our understanding of dementias.

The development of synapses and their maintenance during ageing is dependent on sustained transport of synaptic proteins from the distant soma, driven by motor proteins which trail along the bundles of microtubules in axons and dendrites ([@bib17]). Microtubules are regulated by microtubule binding proteins which are therefore in a key position to regulate synapse formation and maintenance ([@bib46]).

Tau is a microtubule associated protein (MAP) discovered in the mid-seventies ([@bib64]). Reduction in Tau levels has been linked to intellectual disability ([@bib50]) and a class of brain disorders termed \'dementias which lack distinctive histopathology\' (DLDH) ([@bib67]). Tau detachment from MTs is linked to prominent neurodegenerative diseases such as Alzheimer\'s disease, Frontotemporal Dementia and some forms of Parkinson's disease ([@bib28]). In vitro, Tau has the ability to regulate microtubule properties including stability, cross-linkage and polymerisation ([@bib39]). Through such functions, Tau would be expected to regulate multiple aspects of neuronal cell biology, but its physiological roles are still not understood and highly debated ([@bib39]). This might partly be due to experimental challenges posed by functional redundancy, where other MAPs are proposed to mask physiological roles of Tau ([@bib37]; [@bib61]).

A good model in which to deal with functional redundancy is the fruit fly *Drosophila melanogaster*. As is ideal for studies of Tau, *Drosophila* neurons provide access to powerful genetics, they are readily established for research on the neuronal cytoskeleton ([@bib60]), on neuronal transport ([@bib52]) and on synapses ([@bib44]). Importantly, concepts and mechanisms gained from work in flies are often well conserved in higher organisms ([@bib3]; [@bib25]).

Work in *Drosophila* suggested that the spectraplakin Short Stop (Shot), a large actin-MT linker molecules and potent regulators of microtubules, could display potential functional overlap with Tau during microtubule stabilisation ([@bib2]; [@bib46]). This hypothesis is attractive because the well-conserved mammalian spectraplakin Dystonin is already linked to a neurodegenerative disease (type VI hereditary sensory autonomic neuropathy; OMIM \#614653;) ([@bib15]), and its paralogue ACF7/MACF1 plays important roles during brain development ([@bib19]; [@bib26]). Since ACF7 continues to be expressed in the brain, it is tempting to speculate that it might be required for neuronal maintenance ([@bib4]).

Here we use *Drosophila* neurons, in culture and in vivo alike, to demonstrate novel roles of Tau in regulating the formation and maintenance of synapses during ageing, by coordinating the intracellular trafficking of synaptic proteins. Thus, we show that the role of Tau in synapse regulation occurs in functional overlap with Shot. The robust *shot-tau* double-mutant phenotypes enabled us to study the mechanistic cascade composed of three steps: microtubule stability as the trigger, the JNK signalling pathway as the mediator and kinesin-3 mediated axonal transport of synaptic proteins as the key effector. We propose a new mechanism based on the loss of Tau function which could explain intellectual disability in MAPT (the human tau gene) mutant individuals and precocious synapse loss in tau-related neurodegeneration ([@bib51]; [@bib54]).

Results {#s2}
=======

Tau is required for the formation of synapses {#s2-1}
---------------------------------------------

To study synaptic roles of *Drosophila* Tau, we first used primary *Drosophila* neurons generated from *tau* mutant embryos. Primary fly neurons are genetically and experimentally highly amenable and provide robust cellular and subcellular readouts ([@bib45]). These cultures are also particularly suited for the study of embryonic lethal mutations since they allow the examination of neurons beyond the embryonic lethal stage. Already 8 hr in vitro (HIV), these neurons show transport of synaptic material in the growing axon ([@bib60]) and after 2 days in vitro (DIV), they display functional presynaptic sites ([@bib30]; [@bib29]) that can be reliably stained with antibodies against presynaptic proteins ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). They contain dense bars and synaptic vesicle accumulations which undergo excitation-dependent uptake and release ([@bib30]; [@bib29]).10.7554/eLife.14694.003Figure 1.Tau and Shot are required for the formation of synaptic specialisations in axons.(**A**) Primary neurons at 2 DIV obtained from embryos that were wildtype (wt), *tau^-/-^*, and *tau^-/-^*with *elav-Gal4* driven expression of *UAS-tau-GFP*; neurons were stained for tubulin (Tub, red) and the synaptic protein Synaptotagmin (Syt, light blue). (**B**) Quantification of the experiment shown in **A**, shown as the number of Syt puncta per neuron, normalised to wildtype (the assessed numbers of neurons are indicated in each bar, \*\*\*P~MW~\<0.001, \*\*P~MW~\<0.01). (**C**) Primary *Drosophila* neurons at 2DIV, obtained from embryos that were wildtype (wt), *tau^MR22^*(*tau^-/-^*)*, shot^3^*(*shot^-/-^*), and *shot^3^ tau^MR22^*(*shot^-/-^ tau^-/-^*), co-stained with antibodies against HRP (magenta) and the synaptic proteins (green) Syt and Bruchpilot (Brp); areas emboxed with dashed lines are displayed as magnified insets showing the synaptic staining only. (**D**) Quantification of the experiments in **C**, displayed as number (no.) of Syt and Brp puncta per neuron, normalised to wildtype (the assessed numbers of neurons are indicated in each bar, \*\*\*P~MW~\<0.001; \*\*P~MW~\<0.01; \*P~MW~\<0.05,). Scale bar: 10 µm. A statistics summary of the data shown here is available in [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.003](10.7554/eLife.14694.003)10.7554/eLife.14694.004Figure 1---source data 1.Summary of the statistics from [Figure 1B and C](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.004](10.7554/eLife.14694.004)10.7554/eLife.14694.005Figure 1---figure supplement 1.Co-localisation of presynaptic markers reveals presynaptic specialisations.Primary *Drosophila* neurons at 2 DIV co-stained with antibodies against the neuronal marker HRP (red) and different presynaptic proteins (green and blue) including Synaptotagmin (Syt), Synapsin (Syn), neuronal Synaptobrevin (nSyb) or Bruchpilot (Brp); whole neurons are shown, with chevrons indicating somata and the emboxed areas indicating the distal axons shown as threefold manified close-ups; presynaptic proteins show a high degree of co-localisation in the axons, 91% co-localisation of Synapsin (Syn) and Synaptotagmin (Syt) labelled spots (sample size = 24 neurons), 84.7% of Syt and Bruchpilot (Brp) (sample size = 8 neurons), and 81% of neuronal Synaptobrevin (nSyb) with Brp (sample size = 8 neurons), suggesting that the majority of dots represent presynaptic specialisations. Scale bar: 10 µm**DOI:** [http://dx.doi.org/10.7554/eLife.14694.005](10.7554/eLife.14694.005)10.7554/eLife.14694.006Figure 1---figure supplement 2.Rescue experiments with Shot and Tau demonstrate redundant roles in synapses.(**A**) Primary neurons at 2 DIV obtained from embryos that were wildtype (wt), *shot^-/-^*with *elav-Gal4* driven expression of *UAS-shot-GFP, shot^-/-^*with *sca-Gal4* driven expression of *UAS-tau-GFP*, and *tau^-/-^*with *elav-Gal4* driven expression of *UAS-shot-GFP*; neurons were stained for tubulin (Tub, magenta) and Syt (green). (**B**) Quantification of the experiment in **A**, shown as the number of Syt puncta per neuron, normalised to wildtype (the assessed numbers of neurons are indicated in each bar, \*\*\*P~MW~\<0.001; \*P~MW~\<0.05; ns, not significant P~MW~\>0.05). Scale bar: 10 µm. A statistics summary of the data shown here is available in [Figure 1---figure supplement 2---source data 1](#SD2-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.006](10.7554/eLife.14694.006)10.7554/eLife.14694.007Figure 1---figure supplement 2---source data 1.Summary of the statistics from [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.007](10.7554/eLife.14694.007)

The *Df(3R)tauMR22* mutation (*tau^MR22^*) is an embryonic lethal chromosome deletion that uncovers most of the *Drosophila tau* gene and is a true null allele ([@bib5]; [@bib12]). We found that *tau^MR22^* mutant primary neurons at 2 DIV show a decrease in the number of puncta positive for Bruchpilot (Brp) and Synaptotagmin (Syt) (Bruchpilot/Brp: 42%; Synaptotagmin/Syt: 59%; all compared to wildtype control neurons; [Figure 1](#fig1){ref-type="fig"}). Our finding suggest that tau-deficient primary neurons contain fewer Brp and Syt positive presynaptic specialisations. In the following, we will refer to this phenotype as synapse reduction.

To confirm that this reduction in synapse numbers was due to the loss of Tau, we performed rescue experiments using Gal4-induced neuronal expression of *UAS-tau-GFP* ([@bib12]) in *tau^MR22^* mutant neurons. We found a significant improvement of the *tau^MR22^* mutant phenotype ([Figure 1A--B](#fig1){ref-type="fig"}). We concluded that absence of Tau causes a reduction in presynaptic sites.

Tau displays functional overlap with the spectraplakin Shot {#s2-2}
-----------------------------------------------------------

To assess potential functional overlap of Tau with the *Drosophila* spectraplakin Shot, we first analysed *shot^3^* mutant primary neurons at 2 DIV. We found a reduction in synapse numbers (Brp: 62%; Syt: 67%; [Figure 1C--D](#fig1){ref-type="fig"}), consistent with previous descriptions in vivo ([@bib36]; [@bib43]). We confirmed that this reduction in synapse numbers was due to the loss of Shot by using Gal4-induced neuronal expression of *UAS-shot-GFP* ([@bib2]; [@bib59]) which significantly rescued the synapse phenotype in *shot^3^* mutant neurons ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), confirming the involvement of Shot.

We then assessed potential functional overlap of Shot and Tau. First, we analysed primary neurons double-mutant for the *shot^3^* and *tau^MR22^* null alleles (*shot-tau*) which showed even lower synapse numbers (Brp: 22%; Syt: 39%; [Figure 1C--D](#fig1){ref-type="fig"}) than either of the single mutant neurons. Notably, these analyses were performed on clearly polarised neurons with well developed axons to exclude indirect effects caused by defective axon growth ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Despite that, we found that the double-mutant neurons displayed reduced branch numbers ([Figure 3---figure supplement 3F](#fig3s3){ref-type="fig"}). However, we could demonstrate that the lower number in branches is not the cause for synapse reduction by using knock-down experiments as well as rescue experiments (explained in detail below, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"} and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}, see also Discussion).

In further support of functional overlap, also our genetic interaction studies revealed a synapse reduction phenotype in *shot^3/+^ tau^MR22/+^*double heterozygous mutant neurons (see later in Figure 5A). Finally, we performed cross-rescue experiments by expressing a *shot* transgene in *tau^MR22^* mutant neurons and a *tau* transgene in *shot^3^* mutant neurons. In both cases, Syt staining revealed a rescue of the synapse reduction phenotype ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Taken together, our results indicate that Shot and Tau functionally overlap, rather than act hierarchically in the same pathway.

Next, we investigated synaptic phenotypes in vivo. Since *shot^3^* and *tau^MR22^* animals are late embryonic lethal, we analysed them at late embryonic stage 16, when Syt is already confined to nascent synaptic terminals, as can be reliably imaged at neuromuscular junctions (NMJs; [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for a schematic drawing of the embryonic NMJ) ([@bib33]). In *shot-tau* mutant embryos, Syt levels at NMJs were reduced to 48%, whereas *shot* mutant embryos showed a milder reduction to 71%, and *tau* mutant embryos no detectable effect ([Figure 2](#fig2){ref-type="fig"}). Taken together, our data suggest that Tau is required for the formation of synapses in culture and in vivo and that Tau and Shot functionally overlap in this context.10.7554/eLife.14694.008Figure 2.Tau and Shot regulate the localisation of presynaptic proteins at the embryonic NMJ in vivo.(**A**) Images show the dorsal segment of inter-segmental motornerves ([@bib31]) in stage 16 embryos that were wildtype (wt), *tau^MR22^* (tau^-/-^), *shot^3^* (shot^-/-^), and *shot^3^ tau^MR22^* (shot^-/-^ tau^-/-^), stained with antibodies against Syt (green) and the motorneuron-specific cell membrane protein Fasciclin II (FasII, magenta). Arrowheads depict the distal end of the motoraxons where the nascent NMJs are forming; boxed areas are displayed as enlarged insets showing anti-Syt staining only. Note that cell bodies of sensory neurons contain visible levels of Syt in the mutant (white arrows) but not in wildtype neurons (open arrow). (**B**) Quantification of the experiments in **A**, shown as the average intensity of Syt at the nerve ending normalised to wildtype (the sample number of NMJs is indicated in each bar, \*\*\*P~MW~\<0.001; \*\*P~MW~\<0.01; \*P~MW~\<0.05; ns, not significant P~MW~\>0.05). Scale bars: 10 µm. A statistics summary of the data shown here is available in [Figure 2---source data 1](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.008](10.7554/eLife.14694.008)10.7554/eLife.14694.009Figure 2---source data 1.Summary of the statistics from [Figure 2B](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.009](10.7554/eLife.14694.009)10.7554/eLife.14694.010Figure 2---figure supplement 1.Schematic drawings of embryonic tissues analysed in this study.(**A**) Schematic horizontal view of the embryonic nervous system (brain; OL, optic lobe; vNC, ventral nerve cord) showing an exemplary motorneuron (dark blue), muscle (green) and sensory neuron (red). Note that cell bodies in the nervous system lie in the cortex (Cx), i.e. outside the synaptic area (Np, neuropile), and that sensory neurons are positioned in the periphery, often adjacent to synaptic endings of motorneurons (NMJs, neuromuscular junctions). Synapses are shown as yellow dots. The stippled blue frame shows the area (rotated 90 degrees clockwise) shown in [Figures 5C,D](#fig5){ref-type="fig"}, [8F](#fig8){ref-type="fig"}. (**B**) More detailed representation of the periphery with muscles, motorneuronal projections and sensory neurons (same colours as in A). The stippled blue frame emboxes the area shown in [Figures 2](#fig2){ref-type="fig"}, [4E](#fig4){ref-type="fig"}, [5C,E](#fig5){ref-type="fig"}, [6D,F](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"} and [8C](#fig8){ref-type="fig"}, including an arrow head pointing at the most dorsal NMJ and arrow indicating somata of sensory neurons.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.010](10.7554/eLife.14694.010)

Synapse maintenance in the ageing brain requires Tau and Shot {#s2-3}
-------------------------------------------------------------

Tau and Shot remain highly expressed in mature neurons (see later in Figure 6), and we tested whether they are required also for synapse maintenance. For this, we used the GAL4-UAS system to co-express previously used and validated *UAS-*RNAi constructs for both genes in the same neurons ([@bib5]; [@bib58]). This strategy takes out Tau and Shot functions with some delay, due to the late onset of GAL4 expression and the persistence of Tau and Shot proteins ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

We first used this approach in cultured primary neurons, where combined knock-down of *tau* and *shot* caused no reduction in the number of Syt-labelled presynaptic sites at 3 and 18 DIV as compared to wildtype controls ([Figure 3A--B](#fig3){ref-type="fig"}), indicating normal synapse development. However, at 26 DIV, Syt puncta in knock-down neurons were reduced to 41% ([Figure 3A--B](#fig3){ref-type="fig"}), which was comparable to the *shot-tau* double-mutant phenotype at 2 DIV ([Figure 1](#fig1){ref-type="fig"}). At all time points (i.e. 3, 18 and 26 DIV), there were no measurable changes in axonal length nor in branch number when compared to control neurons ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}) clearly indicating that the strong reduction in Syt positive synapses in 26 DIV knock-down neurons was not a secondary effect of morphological changes such as in number of branches and axonal length ([Figure 3A and B](#fig3){ref-type="fig"}).10.7554/eLife.14694.011Figure 3.Tau and Shot are required for the maintenance of synaptic markers in cultured neurons and the ageing adult fly brain.(**A**) Primary neurons at 3 DIV and 26 DIV cultured from embryos that were wildtype or jointly expressing *UAS-tau^RNAi^* and *UAS-shot^RNAi^ *in all neurons driven by the pan-neuronal driver *elav-Gal4 (tau^RNAi^ shot^RNAi^*). Neurons are stained with anti-tubulin and anti-Syt; at 26 DIV, *tau^RNAi^ shot^RNAi^*neurons display a reduction in the number of Syt puncta when compared to wildtype. (**B**) Quantification of the experiments in **A**, shown as the number of Syt puncta per neuron at 3 DIV, 18 DIV and 26 DIV, normalised to wildtype controls (the number of assessed neurons is indicated in each bar; \*\*\*P~MW~\<0.001; ns, not significant P~MW~\>0.05). (**C**) A region of *Drosophila* adult brains including the medulla (delimited by dashed lines) where Syt-GFP is expressed in dorsal cluster neurons using *atonal*-Gal4, in the absence (control) or together with *tau^RNAi^* and *shot^RNAi^* (*tau^RNAi^ shot^RNAi^*). Brains are stained with anti-GFP at 2--5 days (young) and 24--29 days (old) after eclosion. Note that GFP-labelled synapses (arrowheads) are decreased in old brains upon *shot* and *tau* knock-down. (**D**) Quantification of the experiments in **C**, showing the normalised number of Syt-GFP-labelled puncta in old specimen per mean number of puncta in young specimens for the following phenotypes: *ato-Gal4 UAS-syt-GFP* alone (*control*), co-expressing *UAS-tauRNAi (tau^RNAi^), UAS-shot^RNAi^*(*shot^RNAi^*), or both knock-down constructs (*tau^RNAi^ shot^RNAi^*; the number of analysed brains is indicated in each bar, \*\*\*P~MW~\<0.001; ns, not significant P~MW~\>0.05). (**E**) Brain regions as in **C**, of animals expressing the membrane marker myr-tdTomato driven by *ato-Gal4* revealing the morphology of the projections of dorsal cluster neurons within the medulla ; brains were from adults at 2--5 days (young) and 24--29 days (old) after eclosure, expressing myr-tdTomato either alone (control) or together with *tau^RNAi^* and *shot^RNAi^*(*tau^RNAi^ shot^RNAi^*). (**F**) Quantification of the experiments in **E**, displayed as number of branches per axon projecting into the medulla (the number of axons analysed is indicated in each bar; ns, not significant P~MW~\>0.05). Scale bar: 10 µm in **A** and 40 µm in **C** and **E**. A statistics summary of the data shown here is available in [Figure 3---source data 1](#SD4-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.011](10.7554/eLife.14694.011)10.7554/eLife.14694.012Figure 3---source data 1.Summary of the statistics from [Figure 3B,D,F](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.012](10.7554/eLife.14694.012)10.7554/eLife.14694.013Figure 3---figure supplement 1.Delayed effect of RNAi mediated knock-down of Shot and Tau.(**A**) Primary neurons at 3 DIV and 25 DIV cultured from embryos that were wildtype or jointly expressing *UAS-tau^RNAi^* and *UAS-shot^RNAi^*in all neurons driven by the pan-neuronal driver *elav-Gal4 (tau^RNAi^ shot^RNAi^*). Neurons are stained with antibodies against Tau, Shot and Tubulin (red, green and blue respectively); images on the right show: a selected axon segment taken from the main image (top) followed by grey scale images of the separated channels for Tau (2^nd^ from top), Shot (3^rd^ from top) and Tubulin (bottom). At 25 DIV, *tau^RNAi^ shot^RNAi^*neurons display a reduction in both Tau and Shot when compared to wildtype. (**B**) Quantification of the experiments in **A**, shown as mean intensity of Tau or Shot signal per neuron at 3 DIV and 25 DIV, normalised to wildtype controls (30--39 neurons were assessed per genotype; \*\*\*P~MW~\<0.001; \*\*P~MW~\<0.01; ns, not significant P~MW~\>0.05). Comparative data for *shot^3^* and *tau^MR22^* homozygous mutant neurons are given as control, indicating low Tau background staining and incomplete knock-down of Tau at 3 DIV, but high Shot background suggesting strong or complete Shot knock-down at 25 DIV. A statistics summary of the data shown here is available in [Figure 3---figure supplement 1---source data 1](#SD5-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.013](10.7554/eLife.14694.013)10.7554/eLife.14694.014Figure 3---figure supplement 1---source data 1.Summary of the statistics from [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.014](10.7554/eLife.14694.014)10.7554/eLife.14694.015Figure 3---figure supplement 2.Schematic drawings of brain areas analysed in this study.Dorso-fronto-lateral view onto a schematic adult CNS composed of the brain and ventral nerve cord (vNC). Beige areas indicate some synaptic areas, in particular the ventral nerve cord neuropile (Np) and the optic lobes (OL) composed of lamina (1), medulla (2), lobula (3) and lobula plate (4). DCN neurons project to the optic lobe of the contralateral brain half where they branch out in a layered fashion. The blue stippled frame and image inset embox the area (rotated 90 degrees counterclockwise) shown in [Figures 3E](#fig3){ref-type="fig"} and [8E](#fig8){ref-type="fig"} without and with synaptic markers (yellow dots), respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.015](10.7554/eLife.14694.015)10.7554/eLife.14694.016Figure 3---figure supplement 3.Loss of function mutations in *shot* and *tau* induce morphological changes.(**A**--**D**) Representative examples of the shape of primary neurons at 2 DIV obtained from embryos that were wildtype (wt, A), *shot^3^ tau^MR22^ (shot^-/-^ tau^-/-^*B), shot*^-/-^ tau^-/-^* with *elav-Gal4* driven expression of *UAS-unc-104 (shot^-/-^ tau^-/-^ UAS-unc-104,* C) and *shot^3^ tau^MR22^ wnd^2^ (shot^-/-^ tau^-/-^ wnd^-/-^* D). (**E--F**) Quantification of morphological parameters of experiment in (**A**--**D**), including the length of axons (**E**) and the number of branches (**F**), (the assessed numbers of neurons are indicated in each bar, \*\*\*P~MW~\<0.001; ns, not significant P~MW~\>0.05). Note that *wnd^2^ (wnd^-/-^)* restored the number of branches in *shot-tau* mutant neurons, suggesting that JNK not only mediates synapse regulation but also morphogenetic processes downstream of the Shot-Tau deficiency. A statistics summary of the data shown here is available in Figure 3---figure supplement 3---source data 1.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.016](10.7554/eLife.14694.016)10.7554/eLife.14694.017Figure 3---figure supplement 4.RNAi-mediated knock-down of Shot and Tau has no effect on axonal length and branch number.(**A**--**B**) Representative examples of the shape of primary neurons at 3, 18 and 26 DIV obtained from embryos that were wildtype (wt, A) or jointly expressing *UAS-tau^RNAi^* and *UAS-shot^RNAi^ *in all neurons driven by the pan-neuronal driver *elav-Gal4 (tau^RNAi^ shot^RNAi^*, B). (**C**--**D**) Quantification of morphological parameters of experiment in (**A**--**B**), including the length of axons (**C**) and the number of branches (**D**), (the assessed numbers of neurons are indicated in each bar, ns, not significant P~MW~\>0.05). A statistics summary of the data shown here is available in [Figure 3---figure supplement 4---source data 1](#SD6-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.017](10.7554/eLife.14694.017)10.7554/eLife.14694.018Figure 3---figure supplement 4---source data 1.Summary of the statistics from [Figure 1---figure supplement 3C and D](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.018](10.7554/eLife.14694.018)

To assess roles in synapse maintenance also in vivo in the ageing brain, we used *atonal*-*Gal4 (ato-Gal4*) to drive gene expression in dorsal cluster (DC) neurons of the adult brain ([@bib68]) (illustrated in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). In these experiments, we expressed GFP-tagged Synaptotagmin (Syt-GFP) to label synapses, either alone or together with *shot^RNAi^*and/or *tau^RNAi^*. We compared young flies at 2--5 days after eclosion with old flies at 24--29 days at 29oC. We found that the number of Syt-GFP labelled synapses in DC neurons decreased to 34% in aged specimens expressing both *shot^RNAi^ and tau^RNAi^* when normalised to young flies of the same genotype ([Figure 3C--D](#fig3){ref-type="fig"}). This age-dependent decrease in synapse numbers did not occur in control flies ([Figure 3C--D](#fig3){ref-type="fig"}), and single knock-down of either *shot* or *tau* only showed a non-significant tendency to lose synapses over time ([Figure 3D](#fig3){ref-type="fig"}). Notably, aged double knock-down DC neurons had no reduction in the number of axonal branches (as assessed with the myr-tdTomato membrane marker; [Figure 3E--F](#fig3){ref-type="fig"}), indicating that also in vivo precocious synapse decay was not due to axonal loss.

From our studies in culture, in embryos and in the adult brain, we conclude that Tau and Shot are required for synapse development during early stages, and for synapse maintenance in ageing neurons, where their combined deficiency causes precocious synapse loss.

Tau and Shot control intracellular trafficking of synaptic proteins {#s2-4}
-------------------------------------------------------------------

Synapse formation and maintenance require that synaptic proteins synthesised in the soma are actively transported through the axon towards the distant presynaptic sites. In *Drosophila* primary neurons, transport of endogenous synaptic proteins already starts at 8 hr in vitro (HIV) when synaptic proteins appear as dotted patterns along axons and in growth cones ([@bib60]) ([Figure 4A--B](#fig4){ref-type="fig"}). This is similar in rat hippocampal neurons ([@bib6]). Already at this early stage, *shot-tau* double mutant neurons display a strong decrease in synaptic proteins in growth cones and axons ([Figure 4A--B](#fig4){ref-type="fig"}), indicating potential intracellular transport defects.10.7554/eLife.14694.019Figure 4.Intracellular transport of synaptic proteins is defective in *shot-tau* mutant neurons.(**A**) Primary *Drosophila* neurons at 8HIV, obtained from embryos that were wildtype (wt) and *shot-tau (shot^-/-^ tau^-/-^*) stained with antibodies against pan-neuronal HRP (magenta), Syt (green) or nSyb (green); nSyb and Syt are reduced in the growth cones (open versus white arrow heads) but enriched in cell bodies (open versus white arrows) of *shot-tau* mutant neurons. (**B**) Quantification of the experiments from A, given as the number of nSyb or Syt puncta in axons and growth cones; the number of analysed neurons is given in the bars (\*\*\*P~MW~\<0.001). (**C**) Quantification of various transport parameters generated from live movies of axons of wildtype or *shot-tau* mutant neurons (*shot^-/-^ tau^-/-^*) at 8 HIV with *elav-Gal4* driven expression of *UAS-Syt-GFP*. Axonal anterograde and retrograde velocities show only subtle or no alteration in the axons of *shot-tau* neurons. On the contrary, the numbers of vesicles in axons of *shot-tau* neurons are sharply decreased and increased in the somata (\*\*P~MW~\<0.01; \*P~MW~\<0.05; ns, not significant P~MW~\>0.05). (**D**) Magnified views of the somata from primary *Drosophila* neurons at 2 DIV, obtained from wildtype (wt) and *shot-tau *mutant embryos (*shot^-/-^ tau^-/-^*), co-stained with antibodies against Syt. To document the protein content within cell bodies, several z stacks per neuron were obtained and fused as maximal projection; the cell bodies show higher levels of Syt in *shot-tau* mutant neurons as compared to wildtype (number of assessed cells is indicated in the bars, average staining intensity normalised to wildtype; \*\*\*P~MW~\<0.001). (**E**) The dorsal peripheral nervous system (PNS) of wildtype and*shot-tau* embryos at late stage 16 (stages according to) ([@bib8]) stained for Syt (green), FasII (red) and the pan-neuronal nuclear marker Elav (blue). The nascent NMJ at the tip of the inter-segmental motornerve (red) in wildtype contains high levels of Syt (white arrow) whereas the somata of sensory neurons (blue and grey in insets) contain low levels (open arrow); in *shot-tau* homozygous embryos the somata of sensory neurons have high levels of Syt (arrow and inset), whereas there is only little staining at the nerve tip (open arrowhead). Scale bars: 10 μm in A, 5 μm in D and 5 μm in E. A statistics summary of the data shown here is available in [Figure 4---source data 1](#SD7-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.019](10.7554/eLife.14694.019)10.7554/eLife.14694.020Figure 4---source data 1.Summary of the statistics from [Figure 4B--D](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.020](10.7554/eLife.14694.020)

To study intracellular transport, we analysed the dynamics of Syt-GFP using live imaging of neurons at 8 HIV. In *shot-tau* mutant neurons, the percentages of anterograde and retrograde displacements and retrograde velocities of Syt-GFP containing vesicles were not affected and anterograde velocities were only slightly increased. In contrast, the number of Syt vesicles within the axon showed a sharp decrease to \~40% in *shot-tau* mutant neurons when compared to controls ([Figure 4C](#fig4){ref-type="fig"}). Notably, this decrease in axonal vesicles is accompanied by an increase in the number of somatic Syt-GFP puncta to \~159% ([Figure 4C](#fig4){ref-type="fig"}). Similarly, endogenous Syt was increased in somata of *shot-tau* mutant neurons, both in culture and in in vivo ([Figure 4D--E](#fig4){ref-type="fig"}).

These phenotypes in *shot-tau* mutant neurons suggested aberrant intracellular trafficking of Syt-containing vesicles, potentially due to a road block in the soma.

Tau and Shot regulate the activity of kinesin-3 {#s2-5}
-----------------------------------------------

Type 3 kinesins are the predominant motors driving axonal transport of synaptic proteins ([@bib23]). This is also the case for the *Drosophila* homologue Unc-104 (also called Imac) ([@bib41]). We found that *unc-104^170^* null mutant primary neurons at 2 DIV have a vast reduction of Syt-stained synapses ([Figure 5A](#fig5){ref-type="fig"}). This phenotype is strikingly similar to the one observed in *shot-tau* mutant neurons, and suggested that Shot-Tau might regulate Unc-104 function.10.7554/eLife.14694.021Figure 5.Defects in kinesin-3 function mediate synaptic deficits in *shot-tau* mutant neurons.Shot and Tau interact with Unc-104 and regulate its subcellular distribution. (**A**) Primary *Drosophila* neurons at 2 DIV, obtained from embryos which were wildtype, homozygous for *unc104^imac170^ (unc104^-/-^*), or triple-heterozygous for *shot^3^ tau^MR22^ unc104^imac170^ mutations* (shot^+/-^ tau^+/-^*unc104^+/-^*), co-stained with antibodies against tubulin (Tub, magenta) and Syt (green). The graph shows the quantification of the data including also *unc104^-/+^* and shot*^-/-^ tau^-/-^*controls. (**B**) Quantification of Syt puncta in two day old neurons, obtained from embryos that were wildtype or shot*^-/-^ tau^-/-^* with *elav-Gal4* driven expression of *UAS-unc-104* (compare [Figure 1D](#fig1){ref-type="fig"}). (**C**) The dorsal peripheral nervous system (PNS) and the central nervous system (CNS) of wildtype and *shot^3^ tau^MR22^ unc104^imac170^*triple heterozygous embryos at late stage 16 (stages according to [@bib8]) stained for Syt (green), FasII (red in upper panel) and the pan-neuronal nuclear marker Elav (blue); for illustration of the imaged tissue see [Figure 2-figure supplement 1.](#fig2s1){ref-type="fig"} The nascent NMJ at the tip of the inter-segmental motornerve (red in upper panels) in wildtype contains high levels of Syt (arrowheads) whereas the somata of sensory neurons (blue; demarcated by dashed lines) contain low levels (open arrows); in *shot^3^ tau^MR22^ unc104^imac170^*triple heterozygous embryos the somata of sensory neurons have high levels of Syt (arrows), whereas there is only little staining at the nerve tip (open arrowhead). In the ventral nerve cord of wildtype (lower panels), Syt is confined to the neuropile (synapse containing CNS compartment; arrowheads) and excluded from the cortex (compartment with the cell bodies of inter- and motorneurons); in the ventral nerve cord of *shot^3^ tau^MR22^ unc104^imac170^*triple heterozygous embryos, there are segmental groups of cell bodies displaying higher Syt levels (arrows). (**D**) Primary *Drosophila* neurons at 2 DIV, obtained from wildtype (wt) and *tau-shot* mutant embryos, stained with antibodies against pan-neuronal HRP (magenta) and Unc-104 (green); Unc-104 in distal axon segments (emboxed and magnified in insets) is enriched in wildtype but much weaker in *shot-tau* mutant neurons (chevrons indicate neuronal somata). Data were quantified as average intensity of Unc-104 at the distal end of the axon divided by the average intensity at the soma. (**E**) Upper and lower panels show the same locations of late stage 16 embryos as shown in **C**, but taken from wildtype and *shot-tau* mutant embryos, stained for FasII (magenta) and Unc-104 (green). Note the stark decrease of Unc-104 at the end of motor nerves (open versus white arrow heads) and the unusual accumulations of Unc-104 in the cell bodies of sensory neurons as well as in the CNS cortex in *shot-tau* embryos (open versus white arrows). In all graphs, the number of assessed neurons is indicated in each bar; \*\*\*P~MW~\<0.001; \*P~MW~\<0.05; ns, not significant P~MW~\>0.05; scale bars: 18 μm in A, 5 μm in C/PNS, 35 μm in C/CNS, 15 μm in D and E/PNS, 35 μm in E/CNS. A statistics summary of the data shown here is available in [Figure 5---source data 1](#SD8-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.021](10.7554/eLife.14694.021)10.7554/eLife.14694.022Figure 5---source data 1.Summary of the statistics from [Figure 5](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.022](10.7554/eLife.14694.022)10.7554/eLife.14694.023Figure 5---figure supplement 1.Expression of Unc-104 rescues synaptic defects in aged adult brains.(**A**) A region of *Drosophila* adult brains including the medulla (see illustration in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}); UAS-nSyb-GFP is expressed in dorsal cluster neurons using *atonal*-Gal4, either alone (control), together with tau^RNAi^ and *shot^RNAi^*(*tau^RNAi^ shot^RNAi^*) or together with tau^RNAi^, *shot^RNAi^ and* UAS-*unc-104* (*tauRNAi shotRNAi UAS-unc-104*). Brains are shown at 2--6 days (young) and 26--30 days after eclosion (old); GFP-labelled synapses are decreased in old brains with *shot-tau* knock-down when compared to controls, and this effect is rescued by the expression of Unc-104. (**B**) Quantification of experiments in **A**, shown as number of GFP-labelled synapses in old specimen per mean number of GFP-labelled synapses in young specimens of the respective genotype (number of analysed brains is indicated in the bars; \*\*\*P~MW~\<0.001; \*\*P~MW~\<0.01; ns, not significant P~MW~\>0.05). Scale bars: 5 μm in **A**. A statistics summary of the data shown here is available in [Figure 5---figure supplement 1---source data 1](#SD9-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.023](10.7554/eLife.14694.023)10.7554/eLife.14694.024Figure 5---figure supplement 1---source data 1.Summary of the statistics from [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.024](10.7554/eLife.14694.024)

To test this hypothesis, we performed genetic interaction studies. We found that primary neurons stained for Syt at 2 DIV and heterozygous for all of the three genes (*shot^-/+^ unc-104^-/+^ tau^-/+^*) displayed significant reduction in the number of Syt-stained synapses when compared to heterozygous condition of the *unc-104* or *shot-tau* mutant alleles alone ([Figure 5A](#fig5){ref-type="fig"}). Also triple-heterozygous mutant embryos at late stage 16 displayed reduced Syt staining at neuromuscular terminals, but increased staining in the cell bodies of CNS and sensory neurons ([Figure 5C](#fig5){ref-type="fig"}; see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for a schematic drawing of the embryonic NMJ and CNS). Therefore, *unc-104^170^* mutant, *shot-tau* mutant, and triple-heterozygous mutant neurons all show similar phenotypes, both in culture and in vivo, suggesting a functional link between these three proteins.

Type 3 kinesins are anterograde motor proteins that move towards axon tips in mouse neurons ([@bib40]), and we also find *Drosophila* Unc-104 to be distally enriched in the axons of primary neurons at 2 DIV and in embryonic motorneurons *in vivo* ([Figure 5D--E](#fig5){ref-type="fig"}). In mouse, this distal localisation was shown to be suppressed when blocking kinesin-3 mobility ([@bib40]). Also in *shot-tau* mutant neurons in culture and in vivo, Unc-104 localisation in distal axons is reduced whereas levels in the somata are increased ([Figure 5D--E](#fig5){ref-type="fig"}), suggesting that insufficient amounts of Unc-104 move from the somata into axons.

To test whether diminished Unc-104 levels in axons are the cause for the synaptic defects in *shot-tau* mutant conditions, we over-expressed Unc-104, which fully restored synapse numbers in *shot-tau* mutant neurons at 2 DIV ([Figures 5B](#fig5){ref-type="fig"} *versus* 1D). Notably, Unc-104 over-expression in *shot-tau* mutant neurons achieved this rescue of synapses in neurons with significantly less axonal branches ([Figure 3---figure supplement 3F](#fig3s3){ref-type="fig"}), clearly demonstrating that both features are regulated independently of each other.

We next examined whether Unc-104 plays comparable roles also during synapse maintenance in the ageing brain. We used the *ato-Gal4* driver ([@bib68]) and co-expressed Unc-104 together with *shot^RNAi^* and *tau^RNAi^*. To label synapses we expressed the presynaptic marker neuronal Synaptobrevin-GFP (nSyb-GFP, due to technical reasons the use of nSyb-GFP was more convenient than Syt-GFP). Consistent with our previous findings with Syt-GFP ([Figure 3C--D](#fig3){ref-type="fig"}), also nSyb-GFP revealed age-dependent synapse reduction upon *shot^RNAi^* and *tau^RNAi^* expression, clearly confirming our previous data ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [8E--F](#fig8){ref-type="fig"}). When Unc-104 was co-expressed, synapse reduction was clearly rescued (Figure 5---figure supplement 1).

Taken together, our data are consistent with a model where Shot-Tau loss generates a road block which inhibits Unc-104 translocation from the soma into axons, causing synaptic defects at developmental stages and in ageing neurons.

Loss of Shot-Tau induces microtubule destabilisation accompanied by changes in JNK activation {#s2-6}
---------------------------------------------------------------------------------------------

To address the mechanistic links from loss of Shot-Tau to aberrant transport and synaptic defects, we focussed on microtubules. Shot localises along microtubules, and *shot* mutant neurons treated with the microtubule-destabilising drug nocodazole display unusual gaps in their axonal microtubule bundles ([Figure 6B--C](#fig6){ref-type="fig"}) ([@bib2]; [@bib59]). Tau also localises along microtubules ([Figure 6A](#fig6){ref-type="fig"}, [Video 1](#media1){ref-type="other"}), and *tau^MR22^*mutant neurons likewise displayed axonal microtubule gaps upon nocodazole treatment which could be rescued with targeted expression of Tau ([Figure 6B--C](#fig6){ref-type="fig"}). Both, *shot* and *tau* mutant neurons treated with nocodazole displayed on average one gap per axon. This number is significantly increased to \~3 gaps in *shot-tau* mutant neurons ([Figure 6B--C](#fig6){ref-type="fig"}), demonstrating that Tau and Shot share a common function in microtubule stabilisation.10.7554/eLife.14694.025Figure 6.Microtubule instability mediates aberrant JNK signalling and synaptic defects.(**A**) Live imaging of *Drosophila* neurons at 2 DIV, obtained from embryos carrying *tau^304^* (a protein trap line where the endogenous tau gene is genomically tagged with GFP) and the microtubule binding protein Jupiter-Cherry. Endogenous Tau (in magenta) is observed in a pattern reminiscent of microtubules, and colocalises with Jupiter (shown in green). (**B**) Axons of *Drosophila* neurons at 6 HIV with the following genotypes: wildtype (*wt), shot^3^ (shot^-/-^), tau^MR22^ (tau^-/-^), tau* rescue (*tau^-/-^ UAS-tau*) and *shot-tau (shot^-/-^ tau^-/-^*). Neurons were treated for 2.5 hrs with vehicle (DMSO) or 20 µM nocodazole, fixed and stained with anti-Tubulin (Tub, magenta and white) and phalloidin (Pha, green). Only *shot^3^*, *tau^MR22^*, and *shot-tau double mutant *displayed gaps in their axonal microtubule bundles upon nocodazole treatment, but not wildtype and *tau* mutant embryos with Tau rescue. (**C**) Quantification of the experiments in B, indicated as the number of breaks in the microtubule staining per axon (number of analysed neurons is indicated in bars; \*\*\*P~MW~\<0.001; \*\*P~MW~\<0.01; ns, not significant P~MW~\>0.05). (**D**) Embryonic motoraxons of wildtype and *shot-tau* embryos at late stage 16 treated with vehicle (DMSO) or 50 nM of the microtubule stabilising drug epothilone B for 3 hr and stained with FasII (magenta) and Syt (green); in wildtype, the nascent NMJ at the nerve tip contains high levels of Syt (arrowheads); in *shot-tau* embryos there is only little Syt staining at the nerve tip (open arrowhead). Treatment of *shot-tau* embryos with 50nM epothilone B increases the levels of Syt at the tip of motornerves (arrowheads). (**E**) Quantification of the experiments shown in **D**, measured as the average intensity of Syt at nascent NMJs and normalised to wildtype (number or assessed NMJ is indicated in bars; \*\*\*P~MW~\<0.001; ns, not significant P~MW~ \>0.05). (**F**) Upper (PNS) and lower (CNS) panels show the same locations of late stage 16 wildtype embryos as shown in [Figure 5C](#fig5){ref-type="fig"}, stained for FasII (magenta) and activated phospho-JNK (JNK-P); treatment with 100 µm nocodazole for 2 hrs induced a relocation of JNK-P from nascent NMJs (open versus white arrow heads) to cell bodies of sensory neurons and in the CNS cortex (white versus open arrows). Scale bar: 5 μm in A, 4 μm in B, 10 μm in E, 15 μm in D/PNS and 35 μm in D/CNS. A statistics summary of the data shown here is available in [Figure 6---source data 1](#SD10-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.025](10.7554/eLife.14694.025)10.7554/eLife.14694.026Figure 6---source data 1.Summary of the statistics from [Figure 6C and E](#fig6){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.026](10.7554/eLife.14694.026)10.7554/eLife.14694.027Figure 6---figure supplement 1.Treatment of *shot-tau* mutant neurons with epothilone B, increases the localisation of JNK-P at axonal tips.(**A**) Embryonic motoraxons of wildtype and *shot-tau* embryos at late stage 16 treated with vehicle (DMSO) or 50 nM of the microtubule stabilising drug epothilone B for 3 hr and stained with FasII (magenta) and JNK-P (green); In wildtype, JNK-P is high at nerve endings (white arrowheads) and below detection levels in cell bodies of sensory neurons and in the CNS cortex (open arrows). This pattern is inverted in *shot-tau* embryos where JNK-P levels are low at nerve tips (open arrowhead) and high in cell bodies of sensory neurons and in the CNS cortex (white arrows). Treatment of *shot-tau* embryos with 50 nM epothilone B increases the levels of JNK-P at the tip of motornerves (white arrowheads). (**B**) Quantification of the experiments shown in A, measured as the average intensity of JNK-P at nascent NMJs and normalised to wildtype (number of assessed NMJ is indicated in bars; \*\*\*P~MW~\<0.001). Scale bars: 15 μm in PNS panels and 35 μm in CNS panels. A statistics summary of the data shown here is available in [Figure 6 ---figure supplement 1---source data 1](#SD11-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.027](10.7554/eLife.14694.027)10.7554/eLife.14694.028Figure 6---figure supplement 1---source data 1.Summary of the statistics from [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.028](10.7554/eLife.14694.028)

To test whether their roles in microtubule stabilisation and synapse regulation are linked, we treated *shot-tau* mutant embryos at early stage 16 for 3 hr with the microtubule-stabilising drug epothilone B ([@bib18]). We found a significant rescue of Syt levels at motoraxonal endings, which was not observed in vehicle-treated controls ([Figure 6D--E](#fig6){ref-type="fig"}). Therefore, a decrease in microtubule stability is a likely cause for defective transport of synaptic proteins in *shot-tau* mutant neurons. It could be argued that Shot-Tau dependent microtubule stabilisation directly regulates processive advance of kinesins in axons (see Discussion), yet the rather normal transport dynamics we observed upon live imaging in *shot-tau* mutant neurons clearly excluded this possibility ([Figure 4C](#fig4){ref-type="fig"}).

Instead, we hypothesised that microtubule aberration indirectly promotes a transport roadblock in somata. As a potential mediator, we suspected the JNK signalling pathway which is known to respond to a number of cellular stresses (see Discussion). To test our hypothesis, we investigated the pattern of JNK activity, using an antibody against phosphorylated JNK (JNK-P) ([@bib32]). In wild type embryos at stage 16, we found high accumulations of JNK-P at motoraxon tips and low levels in the somata of CNS and sensory neurons ([Figures 6F](#fig6){ref-type="fig"} and [7A](#fig7){ref-type="fig"}), i.e. a localisation pattern similar to that of synaptic proteins and Unc-104 ([Figure 5C--E](#fig5){ref-type="fig"}). This distribution was altered in single *tau^MR22^*or *shot^3^* mutant embryos, showing higher levels of JNK-P in neuronal somata and lower levels at the tips of motoraxons ([Figure 7A](#fig7){ref-type="fig"}). This altered pattern was intensified in *shot-tau* double mutant neurons ([Figure 7A](#fig7){ref-type="fig"}) and clearly reminiscent of the redistribution patterns observed with synaptic proteins and Unc-104 in these neurons ([Figures 4E](#fig4){ref-type="fig"} and [5E](#fig5){ref-type="fig"}). Notably, these changes in the pattern of JNK activation were reproduced when inducing microtubule stress by applying nocodazole to early stage 16 wildtype embryos ([Figure 6F](#fig6){ref-type="fig"}). Complementary to this finding, treatment of *shot-tau* mutant neurons with the microtubule stabilising drug epothilone B, increased the localisation of JNK-P at axonal tips and reduced the aberrant localisation in somata ([Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}).Video 1.Live imaging of *Drosophila* neurons at 2 DIV, obtained from embryos carrying *tau^304^* (a protein trap line where the endogenous tau gene is genomically tagged with GFP) and the microtubule binding protein Jupiter-Cherry.Endogenous Tau (in green) is observed in a pattern reminiscent of microtubules, and colocalises with Jupiter (shown in red). The time laps were obtained every 15 s with a 3i Marianas Spinning Disk Microscope.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.029](10.7554/eLife.14694.029)10.7554/eLife.14694.02910.7554/eLife.14694.030Figure 7.Activated JNK correlates with the subcellular localisation of Unc-104 and Syt.Upper (PNS) and lower (CNS) panels in A-C show the same locations of late stage 16 embryos as shown in [Figure 5E](#fig5){ref-type="fig"}, but embryos are of different genotypes and stained with different antibodies, as indicated; genotypes: wildtype (*wt), shot^3^ (shot^-/-^), tau^MR22^ (tau^-/-^), shot-tau (shot^-/-^ tau^-/-^), elav-Gal4* driven expression of *UAS-hep^ac^ (UAS-hep^ac^*); used antibodies detect FasII (magenta), Syt (green), Unc-104 (green), activated phospho-JNK (JNK-P). (**A**) In wildtype, JNK-P is high at nerve endings (white arrow heads) and below detection levels in cell bodies of sensory neurons and in the CNS cortex (open arrows); this pattern is inverted in *tau^MR22^* and *shot^3^* mutant embryos and even stronger in *shot-tau* embryos, i.e. Syt is reduced at nerve endings (open arrowheads) and upregulated in cell bodies (white arrows). (**B**, **C**) Artificial activation of JNK with neuronal expression of Hep^ac^ suppresses high levels of Unc-104 and Syt at nascent NMJs (open versus white arrow heads) and increases their levels in cell bodies (white versus open arrows). Scale bars: 15 μm in PNS panels and 35 μm in CNS panels.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.030](10.7554/eLife.14694.030)

These data suggested a cascade of events where *shot-tau* mediated microtubule destabilisation or stress triggers abnormal JNK activation in somata which, in turn, causes a somatic block of Unc-104 mediated synaptic transport. In strong support of this hypothesis, the three key players of this cascade, JNK-P, Unc-104 and synaptic proteins, show a striking correlation by concentrating unanimously at axon tips in wildtype, but in somata in *shot-tau* mutant neurons ([Figures 4E](#fig4){ref-type="fig"}, [5E](#fig5){ref-type="fig"} and [7A](#fig7){ref-type="fig"}).

Aberrant JNK signalling upon Shot-Tau loss causes the somatic road-block of Kinesin-3 transport and synaptic defects {#s2-7}
--------------------------------------------------------------------------------------------------------------------

To prove that JNK acts downstream of *shot-tau* to regulate Unc-104, we first expressed a constitutively active variant of the MAPKK Hemipterous (Hep^AC^), a known activator of the JNK pathway ([@bib16]). In late stage 16 embryos, indiscriminate JNK activation through Hep^AC^ triggered an accumulation of Unc-104 and Syt in somata and a decrease of both proteins at axon tips ([Figure 7B--C](#fig7){ref-type="fig"}). Also in primary mature neurons at 2 DIV, Hep^AC^ caused a reduction in the number of synapses to 43% ([Figure 8A--B](#fig8){ref-type="fig"}). Therefore, Hep^AC^ expression mimicked the defects observed in *shot-tau* mutant neurons, consistent with a model where aberrant JNK pathway activation upon Shot-Tau loss causes the somatic block of Unc-104-dependent synaptic transport.10.7554/eLife.14694.031Figure 8.Inhibition of the JNK pathway rescues synaptic defects in *shot-tau* mutant neurons.(**A**) Primary *Drosophila* neurons at 2 DIV, obtained from embryos of the following genotypes: wildtype (wt), *elav-Gal4* driven expression of *UAS-hep^ac^ (UAS-hep^ac^), tau^MR22^ (tau^-/-^), wnd^2^ (wnd^-/-^), tau^-/-^* with *elav-Gal4* driven expression of *UAS-*puc (tau^-/-^ UAS-puc), *tau^MR22^ kay^2^ (tau^-/-^ kay^-/-^*) and *shot^3^ tau^MR22^ wnd^2^ (shot^-/-^ tau^-/-^ wnd^-/-^*), all stained with antibodies against Tubulin (tub, magenta) and Syt (green). Insets correspond to emboxed areas and show a magnified view of the Syt staining. (**B**) Quantification of experiments in **A**, shown as the number of Syt puncta normalised to wildtype (number of assessed neurons is shown in the bars, \*\*\*P~MW~\<0.001; \*\*P~MW~\<0.01; \*P~MW~\<0.05; ns, not significant P~MW~\>0.05). (**C**) Inter-segmental motornerves in the dorsal area of wildtype and *shot^3^* mutant embryos at late stage 16, stained against FasII (magenta) and Syt (green); insets correspond to emboxed areas and show a magnified view of the most dorsal nascent NMJs stained for Syt; note the rescue of Syt localisation if Wnd is absent in *tau-shot* mutant background. (**D**) Quantification of the experiments in **C**, measured as the average intensity of Syt normalised to wt (number of assessed NMJs is shown in the bars; \*\*\*P~MW~\<0.001; \*P~MW~\<0.01). (**E**) A region of *Drosophila* adult brains including the medulla; UAS-nSyb-GFP is expressed in dorsal cluster neurons using *atonal*-Gal4, either alone (control), together with tau^RNAi^ and *shot^RNAi^ *(*tau^RNAi^ shot^RNAi^*) or together with tau^RNAi^, *shot^RNAi^ and* UAS-*bsk^DN^*. Brains are shown at 2--6 days (young) and 26--30 days at 29°C after eclosion (old); GFP-labelled synapses are decreased in old brains with *shot-tau* knock-down when compared to controls, and this effect is rescued by the expression of Bsk^DN^. (**F**) Quantification of experiments in **E**, shown as number of GFP-labelled synapses in old specimen per mean number of GFP-labelled synapses in young specimens of the respective genotype (number of analysed brains is indicated in the bars; \*\*\*P~MW~\<0.001; \*\*P~MW~\<0.01). Scale bars: 5 μm in A, 10 μm in **C** and 40 μm in **E**. A statistics summary of the data shown here is available in [Figure 8---source data 1](#SD12-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.031](10.7554/eLife.14694.031)10.7554/eLife.14694.032Figure 8---source data 1.Summary of the statistics from [Figure 8B,D and F](#fig8){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.032](10.7554/eLife.14694.032)10.7554/eLife.14694.033Figure 8---figure supplement 1.Attenuation of the JNK pathway rescues aberrant Unc-104 localisation in *shot-tau* mutant neurons in culture.(**A**) Primary *Drosophila* neurons at 2 DIV, obtained from wildtype (wt) and *shot^3^ tau^MR22^ wnd^2^*mutant embryos (*shot^-/-^ tau^-/-^ wnd^-/-^*), stained with antibodies against pan-neuronal HRP (magenta) and Unc-104 (green); Unc-104 in distal axon segments (emboxed and magnified in insets) is enriched in wildtype and in *shot^-/-^ tau^-/-^ wnd^-/-^*mutant neurons (chevrons indicate neuronal somata). This is in contrast to *shot-tau* mutant neurons, in which Unc-104 in distal axon segments is much weaker (for reference see [Figure 5D](#fig5){ref-type="fig"}). (**B**) Data were quantified as average intensity of Unc-104 at the distal end of the axon divided by the average intensity at the soma (\*\*P~MW~\<0.01). Scale bars: 5 μm in **A**. A statistics summary of the data shown here is available in [Figure 8---figure supplement 1---source data 1](#SD13-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.033](10.7554/eLife.14694.033)10.7554/eLife.14694.034Figure 8---figure supplement 1---source data 1.Summary statistics from [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.034](10.7554/eLife.14694.034)10.7554/eLife.14694.035Figure 8---figure supplement 2.Attenuation of the JNK pathway rescue aberrant unc-104 localisation in *shot-tau* mutant embryos.(**A**) The dorsal peripheral nervous system (PNS) and the central nervous system (CNS) of wildtype wildtype, *shot^3^ tau^MR22^* and *shot^3^ tau^MR22^ wnd^2^*mutant embryos (*shot^-/-^ tau^-/-^ wnd^-/-^*) at late stage 16 stained with FasII (red), Unc-104 (green) and elav (blue) for the PNS panels and FasII (magenta) and Unc-104 (green) in the CNS panels. Note the stark decrease of Unc-104 at the end of motor nerves (open versus white arrow heads) and the unusual accumulations of Unc-104 in the cell bodies of sensory neurons as well as in the CNS cortex in *shot-tau* embryos (open versus white arrows). This is in contrast to *shot^-/-^ tau^-/-^ wnd^-/-^*mutant neurons in which Unc-104 is increased at the end of motor nerves and decreased in the cell bodies of sensory neurons as well as in the CNS cortex. Scale bars: 15 μm in PNS panels and 35 μm in CNS panels.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.035](10.7554/eLife.14694.035)

If our model is correct, attenuation of the JNK pathway should rescue the synaptic defects in *shot-tau* mutant neurons. To downregulate the JNK pathway, we used loss-of-function of the JNK activating kinase Wallenda/DLK *(wnd^2^*) ([@bib62]) and overexpression of the JNK inhibiting phosphatase Puckered (Puc) ([@bib38]). When combined with the *tau^MR22^* mutation, both genetic tools for JNK downregulation fully rescued the synaptic defects in primary neurons at 2 DIV ([Figure 8A--B](#fig8){ref-type="fig"}). Even more, *wnd^2^* fully rescued synapse reduction in *shot-tau* double mutant neurons at 2 DIV ([Figure 8A--B](#fig8){ref-type="fig"}), and Syt levels at NMJs of *shot-tau* mutant embryos in vivo ([Figure 8C--D](#fig8){ref-type="fig"} *versus* [Figure 2](#fig2){ref-type="fig"}).

So far, our data suggest that JNK acts downstream of *shot-tau* to regulate Unc-104. In this case, attenuation of the JNK pathway should also rescue aberrant Unc-104 localisation in *shot-tau* mutant neurons. Accordingly, *wnd^2^* restored correct localisation of Unc-104 in *shot-tau* double mutant neurons at 2 DIV ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}), and in *shot-tau* mutant embryos *in vivo* ([Figure 8---figure supplement 2B](#fig8s2){ref-type="fig"} *versus* [Figure 5D,E](#fig5){ref-type="fig"}).

Having confirmed JNK as the essential mediator of *shot-tau* synaptic defects, we tested whether it acts through the canonical pathway involving the AP1 transcription factor ([@bib9]), or by phosphorylating other targets in the cytoplasm. For this, we used a well established LOF mutant allele of the *kayak/c-fos* gene (*kay^2^*) which removes one constituent of the AP1 heterodimer and mimics various known JNK mutant phenotypes ([@bib9]). Unlike *wnd^2^*or Puc overexpression, the *kay^2^* mutation failed to rescue the synaptic phenotypes of *tau^MR22^*in primary neurons ([Figure 8A--B](#fig8){ref-type="fig"}). This strongly suggests that the JNK pathway inhibits synaptic transport by acting independently of AP1 dependent transcription.

In conclusion, the JNK pathway is both required and sufficient to mediate between Shot-Tau loss and their downstream synaptic phenotypes in developing neurons by causing a transport roadblock, and this likely occurs through phosphorylating cytoplasmic targets in the soma.

JNK mediates ageing related synaptic decay caused by Shot-Tau loss {#s2-8}
------------------------------------------------------------------

To test whether JNK plays comparable roles also during synapse maintenance in the ageing brain, we used the *ato-Gal4* driver ([@bib68]) and co-expressed a dominant negative variant of the *Drosophila* JNK homolog Basket (*bsk^DN^*) ([@bib1]) together with *shot^RNAi^, tau^RNAi^* and nSyb-GFP. We found that co-expression of *bsk^DN^* was able to rescue the synapse reduction phenotype ([Figure 8E,F](#fig8){ref-type="fig"}), thus confirming JNK as a mediator between the effects of *shot-tau* and precocious synapse decay also in ageing neurons (summarised in [Figure 9](#fig9){ref-type="fig"}).10.7554/eLife.14694.036Figure 9.Schematic model of proposed function for Tau and Shot.(**A**) Neurons illustrating different phenotypes: in wildtype neurons (wt), microtubules are stable (green line) and levels of Unc-104 (red square), synaptic markers (yellow dots) and p-JNK (turquoise background) are high in axon tips; in shot-tau mutant neurons, microtubules are unstable (stippled green lines), and the above listed proteins accumulate in cell bodies (soma); ubiquitous activation of JNK (↑JNK) causes similar somatic accumulation of Unc-104 and synaptic markers; down-regulation of JNK (↓JNK) rescues the *shot-tau* mutant phenotypes. (**B**,**C**) Schematic representation of the underlying mechanisms: In wildtype neurons (**B**), Unc-104 is activated (Unc\*) and mediates axonal transport of synaptic proteins (yellow arrow) to the axon tip, where we propose (?) that active JNK inhibits Unc-104, thus releasing its cargo for synaptic incorporation. In *shot-tau* mutant neurons (C), unstable microtubules cause upregulation of JNK in the soma, thus inhibiting Unc-104 and trapping it as well as its cargo proteins in the soma.**DOI:** [http://dx.doi.org/10.7554/eLife.14694.036](10.7554/eLife.14694.036)

Discussion {#s3}
==========

A new mechanism of synaptic pathology caused by loss of Tau and Shot {#s3-1}
--------------------------------------------------------------------

The aim of our studies was to understand the role of endogenous Tau in neurons with particular attention to synapses. This effort was essentially aided by our finding that Tau and Shot are functionally redundant, and the subsequent incorporation of Shot into our studies. The robust phenotypes of *shot-tau* double-mutant neurons enabled us to demonstrate roles of Shot-Tau during the formation and maintenance of pre-synaptic sites in axons, and unravel the underlying mechanistic cascade which involves three major steps. Firstly, the absence of Shot-Tau causes microtubule destabilisation. Secondly, this cytoskeletal stress causes aberrant JNK activity patterns with upregulation in somata and downregulation at axon tips. Thirdly, aberrant JNK activation leads to a somatic roadblock for kinesin-3 mediated transport, thus inhibiting the delivery of synaptic proteins and eventually causing synapse loss. Depending on whether the functions of Tau and/or Shot are removed during development or ageing, either the formation or the maintenance of synapses are affected, respectively ([Figure 9](#fig9){ref-type="fig"}).

Our model explaining the function of Tau and Shot in synapse establishment and maintenance by regulating intracellular transport, is supported by loss- and gain-of-function experiments, genetic interactions and cross-rescue experiments. The initial finding that *shot-tau* mutant neurons had reduced branch numbers, could have suggested that defects on synapse numbers is indirect. However, experiments with double knock-down in culture and in the adult brain clearly showed strong synapse reduction whilst maintaining normal branch patterns, and Unc-104 rescued synapse reduction in *shot-tau* mutant neurons without major increases of the branch pattern in these neurons. These results clearly demonstrate that changes in neuronal morphology are not the cause of changes in synapse number.

Notably, the synaptic function of Tau described here for *Drosophila* might be conserved in higher animals or humans, since also aged Tau knock-out mice develop a reduction of synaptic proteins from the hippocampus ([@bib37]).

Implications of our findings for Tau-related pathologies {#s3-2}
--------------------------------------------------------

Our findings provide potential new mechanistic explanations for various tau related brain disorders. For example, microdeletions in the region of MAPT (the human tau gene) cause intellectual disability ([@bib50]), and Tau\'s synapse-promoting roles m﻿ay well contribute to this pathology. Furthermore, various tauopathies are characterised by precocious pathological loss of synapses. Our data suggest that loss of tau could lead to defective synapse maintenance and eventually synapse loss. For example, a prominent group of dementias which lacks distinctive histopathology (DLDH) are characterised by the loss of Tau ([@bib67]). Further tauopathies including Alzheimer disease, typically involve hyper-phosphorylation and aggregate formation of Tau ([@bib22]; [@bib65]). In this scenario, there are two parallel, non-exclusive modalities through which Tau can cause pathology. Firstly, detached hyper-phosphorylated tau attains gain-of-function roles in the cytoplasm damaging neurons through a number of mechanisms ([@bib39]). Secondly, hyper-phosphorylation of tau causes a loss-of-function condition by depleting Tau from microtubules. However, since Tau knock-out mouse models mostly failed to show significant phenotypes and the neuronal functions of endogenous tau remain little understood, the pathological importance of Tau loss from microtubules has been marginalised ([@bib39]). Our results now re-emphasise the notion that loss of Tau from microtubules could contribute to neurodegenerative pathology and deliver mechanistic explanations.

To unravel pathomechanisms caused by the loss of Tau, we mostly used combined depletion of Shot and Tau, which gave us strong phenotypes, ideal for short-term experimental approaches. However, we found similar, yet milder phenotypes if only Tau was depleted, suggesting that the mechanisms described here could well contribute to slow disease progression in tauopathies. Our discovery that spectraplakins are MAPs which functionally overlap with Tau, opens up new experimental avenues for Tau studies. So far, spectraplakins have been linked to the degeneration of sensory and autonomous neurons ([@bib13]; [@bib15]), and it remains to be elucidated whether they may have similar roles also in the brain. Our results clearly hint at this possibility.

A novel mechanism for Tau-dependent regulation of neuronal transport {#s3-3}
--------------------------------------------------------------------

The loss of Tau and/or Shot inhibits kinesin-3 mediated transport leading to accumulation of synaptic proteins in the soma of neurons. We propose a road-block mechanism suppressing the initiation of axonal transport in somata of Shot-Tau depleted neurons, which is caused indirectly through microtubule stress and mediated by JNK ([Figure 9](#fig9){ref-type="fig"}).

The involvement of microtubules in causing a transport block is supported by our experiments using microtubule stabilising and de-stabilising drugs which rescued or mimicked the *shot-tau* mutant phenotypes, respectively. Similarly, axonal transport defects and cognitive deficits of *PS19Tg mice* (expressing the P301S mutant form of human *tau)* and various other mouse and fly tauopathy models were shown to be rescued by microtubule-stabilising drugs ([@bib20]; [@bib48]; [@bib56]; [@bib66]), suggesting that the mechanisms we described may be conserved and relevant to disease.

The somatic road-block is a novel mechanism through which the loss of Tau can interfere with the transport of synaptic proteins and provides potential explanations also for somatic accumulations of postsynaptic proteins such as PSD-95, AMPA and NMDA receptors observed in mouse tauopathy models ([@bib24]; [@bib55]). A likely mechanism causing a roadblock in intracellular transport could be the direct inactivation of Unc-104 or its associated adaptor proteins, for example through JNK or other kinases within its pathway. This mode of regulation has a clear precedent in kinesin-1 and its adaptor Jip which are directly phosphorylated by JNK leading to transport inhibition ([@bib57]). Unfortunately, our extensive attempts to co-immunoprecipitate JNK and Kinesin-3 were unsuccessful (data not shown), leaving open for now the exact molecular mechanism.

JNK is an important mediator between *shot-tau* induced microtubule stress and synapse loss {#s3-4}
-------------------------------------------------------------------------------------------

We propose that aberrant JNK activation downstream of microtubule destabilisation or stress is the ultimate cause for the defective delivery of synaptic proteins in Tau and/or Shot loss of function. Also in mouse, microtubule stress leads to somatic activation of the JNK pathway, suggesting this mechanism is likely to be conserved with vertebrates ([@bib63]).

The JNK pathway is emerging as a central player in neurodegenerative diseases. Its activation is prompted by various neurodegeneration risk factors including oxidative stress, inflammation, and ageing ([@bib34]; [@bib63]). Furthermore, JNK is activated in AD patients ([@bib10]) and in several AD models where it triggers progression of the pathology ([@bib53]). The new link between Tau/spectraplakins, JNK and synapses we propose here, is therefore likely to provide mechanistic explanations for synaptic pathology observed in AD and other tauopathies.

Conclusions {#s3-5}
-----------

We have delivered an important conceptual advance by revealing a new mechanistic cascade which can explain synaptic decay as the consequence of Tau loss from microtubules. Furthermore, we identified a previously unknown functional redundancy with spectraplakins as a promising new avenue for research on Tau. Our findings emphasise that Tau detachment from microtubules can be an important aspect contributing to the pathology of tauopathies in parallel to roles of hyper-phosphorylated Tau in the cytoplasm. Synaptic decay, axonal transport and alterations in the JNK pathway are emerging as central players in a wider range of adult-onset neurodegenerative diseases, and here we have aligned these factors into a concrete mechanistic cascade.

Materials and methods {#s4}
=====================

Fly stocks {#s4-1}
----------

The following fly stocks were used: the Gal4 driver lines *sca-Gal4* ([@bib60]), *elav-Gal4* (3^rd^ chromosome) ([@bib35]) and *ato-Gal4* ([@bib68]); the mutant alleles *Df(3R)tauMR22* ([@bib5]; [@bib12]), *shot^3^* ([@bib27]), *unc-104^imac170^* (courtesy of Dr. T. Schwarz) ([@bib41]), *wnd^2^* ([@bib11]) and *kay^2^ *([@bib9]) (the latter two courtesy of S. Sweeney); the UAS lines UAS-*tau-GFP* ([@bib12]), UAS-*shot-GFP* ([@bib2]; [@bib59]). *tau^GD25023^* (UAS-tau*^RNAi^*; Vienna *Drosophila* RNAi Center, Austria) ([@bib5]), UAS-shot*^RNAi^*([@bib58]), UAS-syt*-GFP* (3^rd^ and 2^nd^ chromosome, Bloomington Stock Center), UAS-*nSyb-GFP* (Bloomington Stock Center), UAS-*tdTomato* ([@bib68]), tau^304^ (Bloomington Stock Center), Jupiter-Cherry (Bloomington Stock Center), UAS-*Hep-ac* ([@bib16]), UAS-*bsk^DN^* ([@bib1]) and UAS-*puc* ([@bib38]) (the latter five fly stocks courtesy of B. Hassan). Lethal fly stocks were kept over balancers carrying *twist-Gal4* and *UAS-GFP* constructs ([@bib21]), and combinations of mutant alleles and transgenic constructs were generated using conventional genetic crosses ([@bib46]).

Cell culture {#s4-2}
------------

The generation of primary neuronal cell cultures was described previously ([@bib45]; [@bib60]). In brief, to generate *Drosophila* primary cultures, neurons were extracted from stage 11 embryos ([@bib8]). Whole embryos were treated for 1 min with bleach to remove the chorion, sterilized for \~30 s in 70% ethanol, washed in sterile Schneider's/FCS, and eventually homogenized with micro-pestles in 1.5 ml tubes containing about 21 embryos per 100 μl dispersion medium. This was followed by 4--5 min incubation in dispersion buffer containing collagenase and dispase at 37°C, followed by a wash in sterile Schneider's/FCS and eventually resuspension in the final volume of Schneider's medium. Cells were plated onto coverslips coated with 0.5 mg/ml Concanavalin A (Sigma) and kept as hanging drop cultures in air-tight special culture chambers ([@bib30]) usually for 8 hr, 2--3, 18 or 26 days at 26°C. Dilutions of the MT destabilising drug nocodazole (20 μM; Sigma) in Schneider's medium were prepared from stock solutions in DMSO. For controls, equivalent concentrations of DMSO were diluted in Schneider's medium.

Drug treatment of *Drosophila* embryos {#s4-3}
--------------------------------------

Stage 16 embryos were dissected flat in D﻿ulbecco\'s Phosphate Buffered Saline ([@bib7]) and cultured for several hours in Schneider's medium with or without drugs. Dilutions of the microtubule destabilising drug nocodazole (20 μM; Sigma) and the microtubule stabilizer epothilone B (50 nM; Sigma) in Schneider's medium were prepared from stock solutions in DMSO. For controls, equivalent concentrations of DMSO were diluted in Schneider's medium.

Immunohistochemistry {#s4-4}
--------------------

Primary fly neurons were fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB; pH 7--7.2) for 30 min at room temperature (RT). Stage 16 embryos were dissected flat in Dulbecco\'s Phosphate Buffered Saline ([@bib7]) and fixed with 4% PFA for 30 min. Adult fly brains were dissected in Dulbecco\'s Phosphate Buffered Saline and fixed with 4% PFA for 15 min. Antibody staining and washes were performed with Phosphate Buffered Saline supplemented with 0.3% Triton X-100. Staining reagents: anti-Tubulin (clone DM1A, mouse, Sigma; alternatively, clone YL1/2, rat, Millipore Bioscience Research Reagents); anti-FasII (clone ID4, mouse, DSHB, RRID: [AB_532376](http://antibodyregistry.org/search.php?q=AB_532376)); anti-GFP (goat, Abcam RRID: [AB_305643](http://antibodyregistry.org/search.php?q=AB_305643)); Cy3/FITC-conjugated anti-HRP (goat, Jackson ImmunoResearch); anti-Syn (SYNORF1 3C11, mouse, DSHB, RRID:[AB_528479](http://antibodyregistry.org/search.php?q=AB_528479)); anti-Brp (DSHB, RRID:[AB_2314867](http://antibodyregistry.org/search.php?q=AB_2314867)); anti-Syt (rabbit, was a gift from Dr. S. Sweeney); anti-nSyb and anti-Unc104 (both rabbit, were a gift of Dr. T. Schwarz); anti-Elav (rat, DSHB, RRID:[AB_528218](http://antibodyregistry.org/search.php?q=AB_528218)); anti-pJNK (rabbit, pTPpY, Promega, RRID:[AB_430864](http://antibodyregistry.org/search.php?q=AB_430864)), anti-CD2 (mouse, AbD Serotec, RRID:[AB_566608](http://antibodyregistry.org/search.php?q=AB_566608)), anti-dTau (Nick Lowe), anti-Shot (Talila Volk) FITC-, Cy3- or Cy5-conjugated secondary antibodies (donkey, purified, Jackson ImmunoResearch). Specimens were embedded in Vectashield (VectorLabs).

Microscopy and data analysis {#s4-5}
----------------------------

Standard documentation was performed with AxioCam monochrome digital cameras (Carl Zeiss Ltd.) mounted on BX50WI or BX51 Olympus compound fluorescent microscopes. Z-stacks of embryonic CNSs were taken with a Leica DM6000 B microscope and extracted with Leica MM AF Premier software. Z-stacks of adult fly brains were taken with a Leica DM6000 B microscope or with a 3i Marianas Spinning Disk Confocal Microscope. Using custom software written in Python and NumPy, fly brain images taken with a Leica DM6000 B microscope were individually band-pass filtered (A trous wavelet \[1\]\[2\], linear 3x3 filter, keeping scales 1--4) to remove stationary background.

To quantify the number of synaptic densities in mature neurons in culture and the number of vesicles containing synaptic proteins in 8h neurons in culture, we used ImageJ (RRID:[SCR_003070](https://scicrunch.org/scicrunch/Resources/record/nlx_144509-1/063e0149-a929-5fd5-8968-34dff7e4fd59/search)). In detail, we used thresholding to select synaptic densities from axons of single isolated cells, followed by particle analysis. For all experiments done in parallel, identical thresholds were used. For the quantification of synapses in mature neurons in culture, we selected polarised neurons with a clear distinguishable axon, the same neurons were used to study axon length and number of branches.

To quantify synaptic proteins or Unc-104 in the soma of neurons, we manually selected the area of the somata using the tubulin or HRP channel and measured the signal intensity derived from the Syt or Unc-104 channel. To measure the levels of Unc-104 at the tip of axons, we selected an area of the same size at the most distal part of axons and measured the signal intensity derived from the Unc-104 channel. To quantify synaptic proteins at the tip of embryonic motorneurons in vivo. we manually selected the area occupied by the growth cones using the FasII staining and measured the signal intensity derived from the Syt channel; the background intensity was subtracted. Images used for these measurements did not contain saturated levels. Also, to measure the number of synaptic densities in DC neurons in the medulla of the adult brain, we used thresholding to select synaptic densities followed by particle analysis. The number of branches in the medulla per DC neuron was quantified manually. To quantify MT stability upon nocodazole treatment, we counted the number of breaks in the microtubule bundle per axon.

Time lapse imaging of cultured primary neurons (in Schneider\'s/FCS) was performed on a Delta Vision RT (Applied Precision) restoration microscope using a 100x/1.3 Ph3 Uplan Fl objective and the Sedat filter set (Chroma 89000). The images were collected using a Coolsnap HQ (Photometrics) camera. The temperature control was set to 26°C. For time lapse recording, images were taken every 2 s for 2 min. To generate transport measurements, vesicles containing fluorescently tagged Syt were tracked manually using the manual tracking plugin for ImageJ.

Statistics, replicates and sample-size {#s4-6}
--------------------------------------

All data are shown as mean with SEM. Statistical analyses were performed in GraphPad Prism using Mann-Whitney Rank Sum Tests (indicated as P~MW~) or Chi^2^ (P~Chi~), with 95% confidence intervals. The exact p-values and sample size are indicated in the figure legends.

For each primary neuronal cell culture experiment (technical replication), approximately 30 to 40 embryos were used. Neurons obtained from those embryos were divided and cultured in 3 to 4 independent chambers (biological replication). The sample size provided corresponds to the number or neurons studied. Most experiments were performed at least 2 times (2 technical repeats) meaning a minimum of 60 embryos were used, and a minimum of 6 independent culture chambers were studied. These experiments are shown in [Figure 1B](#fig1){ref-type="fig"} (*tau^-/-^*, 4 technical replications, 11 biological replications), [Figure 1D](#fig1){ref-type="fig"} (Syt, *shot^-/-^*, 3 technical replications, 9 biological replications; *shot^-/-^ tau^-/-^*, 3 technical replications, 9 biological replications), [Figure 1D](#fig1){ref-type="fig"} (Brp *shot^-/-^*, 2 technical replications, 8 biological replications; tau^-/-^ 2 technical replications, 6 biological replications), [Figure 3B](#fig3){ref-type="fig"} (all genotypes at each time point 2 technical replications, 6--8 biological replications), [Figure 4D](#fig4){ref-type="fig"} (all genotypes 2 technical replications, 6 biological replications), [Figure 5B](#fig5){ref-type="fig"} (2 technical replications, 6 biological replications), [Figure 8B](#fig8){ref-type="fig"} (*tau^-/-^ Uas-Puc*, 3 technical replications, 8 biological repeats; *tau^-/-^ wnd^-/-^,* 2 technical replications, 6 biological repeats; *shot^-/-^ tau^-/-^ wnd^-/-^*, 2 technical replications, 6 biological replications). Other experiments were as follows: *UAS-tau* rescue experiment of synaptic defects ([Figure 1B](#fig1){ref-type="fig"}) and microtubule stability defects ([Figure 6C](#fig6){ref-type="fig"}) in *tau^-/-^* were performed with 1 technical replication which included at least 30 embryos distributed in 4 and 2 independent chambers or biological replications, respectively. However, for these particular experiments we used a co-culture technique in which *tau^-/-^*control neurons were cultured alongside with *tau^-/- ^*UAS-Tau neurons and therefore are subject to the same environmental variations. For *shot-tau* mutant neurons stained with Brp ([Figure 1D](#fig1){ref-type="fig"}) we used 1 technical replication which included at least 30 embryos and 3 independent biological replications. For *tau^-/-^ kay^-/-^* and *kay^-/-^* ([Figure 8B](#fig8){ref-type="fig"}), we used 1 technical replication which included at least 30 embryos and 5 independent biological replications. For the measurement of Syt and nSyb synaptic puncta in 8 HIV neurons ([Figure 4B](#fig4){ref-type="fig"}), we performed 1 technical replication for each synaptic protein, which included at least 30 embryos each and 2 independent biological replications. For the measurement of Unc-104 in 2 day neurons ([Figure 5D](#fig5){ref-type="fig"}) we performed 1 technical replication which included at least 30 embryos and 45 neurons were measured. To account for variations in the immunohistochemistry procedure, we calculated the ratio between distal axon and soma.

For the quantification of axonal transport ([Figure 4C](#fig4){ref-type="fig"}), we performed 2 technical replications which included at least 30 embryos each, 2 independent biological replications from which 10--14 neurons were analysed. For measurements of Syt in the nascent embryonic NMJ ([Figure 2B](#fig2){ref-type="fig"} and [8C](#fig8){ref-type="fig"}) we used at least 15 embryos per genotype (biological replication) and performed at least 2 technical replications. Both controls and mutant embryos were dissected and stained in the same chamber and therefore subjected to equal conditions ([Figure 2B](#fig2){ref-type="fig"} shot^-/-^ 3 technical replications, 30 biological replications, tau^-/-^ 2 technical replications, 15 biological replications, shot^-/-^ tau^-/-^ 3 technical replications, 17 biological replications; [Figure 8C](#fig8){ref-type="fig"} shot^-/-^ tau^-/-^wnd^-/-^ 2 technical replications, and 15 biological replications). For treatment of embryos with epothilone B ([Figure 6E](#fig6){ref-type="fig"}) we used at least 12 embryos per genotype and performed 2 technical replications. Both controls and *shot-tau* mutant embryos were present in the same treatment chambers and therefore subjected to equal conditions.

For the study of synaptic phenotypes in adult brains ([Figure 3D](#fig3){ref-type="fig"}), we performed at least 3 technical replications and used a minimum of 30 brains in total per genotype. For the quantification of axonal branches in adult brains we performed at least 2 technical replications and we used a minimum of 11 brains. For rescues of synaptic phenotypes in adult brains with UAS-*bsk^DN^* ([Figure 8F](#fig8){ref-type="fig"}) we performed 3 technical replications and used a minimum of 40 brains in total.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/501100000268Biotechnology and Biological Sciences Research Council BB/M007456/1 to Natalia Sanchez-Soriano.

-   http://dx.doi.org/10.13039/501100000268Biotechnology and Biological Sciences Research Council BB/I002448/1 to Andreas Prokop.

-   http://dx.doi.org/10.13039/100004440Wellcome Trust 105610/Z/14/Z to Andreas Prokop.

-   http://dx.doi.org/10.13039/501100001659Deutsche Forschungsgemeinschaft 2071/1-1 to Andre Voelzmann.

This work was made possible through funding by the BBSRC (BB/M007456/1) to NSS, by the BBSRC (BB/I002448/1) and Wellcome Trust ISSF (105610/Z/14/Z) to AP, and the German Science Foundation (DFG; VO 2071/1-1) to AV. The Bioimaging Facility microscopes used in this study were purchased with grants from the BBSRC, The Wellcome Trust and the University of Manchester Strategic Fund, and the Manchester Fly Facility where flies were kept and genetic crosses performed has been supported by funds from The University of Manchester and the Wellcome Trust (087742/Z/08/Z). We thank Meredith Lees and Egor Zindy for experimental help, Bassem Hassan, Roland Brandt and Nigel Hooper for helpful comments on the manuscript, Thomas Schwarz, Sean Sweeney, Bassem Hassan, Nick Lowe and Talila Volk for kindly providing reagents. Stocks obtained from the Bloomington *Drosophila* Stock Center (NIH P40OD018537) were used in this study.

Additional information {#s5}
======================

The authors declare that no competing interests exist.

AV, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

PO-R, Acquisition of data, Analysis and interpretation of data.

YQ, Acquisition of data, Analysis and interpretation of data.

MC-M, Acquisition of data, Analysis and interpretation of data.

MdC-E, Acquisition of data, Analysis and interpretation of data.

AP, Conception and design, Drafting or revising the article.

NS-S, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents.

10.7554/eLife.14694.037

Decision letter

VijayRaghavan

K

Reviewing editor

Tata Institute of Fundamental Research

,

India

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Tau and spectraplakins promote synapse formation and maintenance through JNK and neuronal trafficking\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and K VijayRaghavan as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Sean Sweeney (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Voelzmann et al. provide a compelling set of data that gives a deep insight into tau function with regard to axon traffic with development and age, by pinpointing a redundancy with short-stop/spectraplakin, and a pathway with kinesin-3/immaculate-connections. They use an elegant series of experiments involving primary culture, in vivo experiments, genetics, pharmacology, ageing and live imaging to demonstrate this. As the discussion states, this data has profound implications for our understanding of tau function in neurodevelopment and neurodegeneration. Yet, the authors try to cover a large area for which they need to support numerous potential causalities.

While the overall idea is strong, there are numerous open ends and insufficiently supported statements in this manuscript to support the cascade-like chain of causalities presented here.

Essential revisions:

The abstract and introduction might be toned down a little and move away from the idea of \'homeostasis\'. This term has become all things to all folks, and \'synaptic maintenance\' or similar phrasing could be used. The authors should take time within the results to explain the experimental system -- i.e. the tau mutants are lethal, and the primary culture allows examination of neurons beyond this lethal stage. For [Figure 1](#fig1){ref-type="fig"}, we would suggest including, or referring to the later figure where double heterozygotes of shot/tau give significant data -- this more directly alludes to the pathway, rather than two loss-of-function mutants making a defective phenotype worse (But see below on this). They also refer often to \'synapses\' when a more precise description of (something like) \'materially deficient\' synapses would be useful. In general it will be useful to make the statements precise and clear. The diagrammatic explanations of the experimental system are beautifully clear, as are the images presented.

The strongest experiments in the paper are the rescue of tau, shot mutants through unc104 overexpression and through JNK attenuation. However, in these cases, only selective read-outs are used (for example, we do not learn whether JNK attenuation affects unc104, as predicted by the model). Sometimes read-outs focus on syt punctae, sometimes brp, n-syb and different ages in culture or in vivo. Different read-outs in different experiments make comparisons more difficult. A principal concern arising from the presentation of selective read-outs is the specificity of the phenotypes. Defective syt puncta (the most commonly used read-out in the paper) can arise directly and indirectly from numerous causes. Just because they become more when there is more kinesin does not mean that the function of tau and shot is truly rescued. I am wondering what these neurons look like, what other markers look like and what aspects of neuronal function and maintenance are truly \'rescued\' with unc104 overexpression compared to the microtubule-stabilizing drug compared to JNK signaling attenuation. Finally, a key issue is the lack of simple genetic rescue experiments. The authors only provide one tau rescue experiments at the beginning of the paper. The shot mutant is never rescued by a shot transgene.

In sum, while we find the paper compelling and interesting substantial revisions are required and should be done within the two month period required by *eLife*.

Required experiments:

1\) Rescue of shot, rescue attempt of tau with shot and rescue attempt of shot with tau. Only these experiment reveal functional overlap. We do not think the rescue of the double mutant with either tau or shot is as meaningful, because the double mutant clearly gets worse than any single and any single rescue in that background would make it better, without revealing functional overlap of the two proteins.

2\) Morphology of the neurons throughout, in mutants and rescues, to show to what extent syt puncta counts are a consequence of more severe neuronal defects.

3\) Further regarding the specificity issue: Please see the reference in the review below to how the original unc104 paper made its point on specificity (mitochondria, HRP, fasII, mCD8, -- subset of these). The key is whether this is a defect specific to synaptic proteins as proposed or a general transport or even health problem of these neurons.

4\) The authors should use UNC-104 as a readout in the rescues and throughout for mutants presented. JNK-P is also key as presented by the authors.

5\) The pharmacological experiments require some level of meaningful rescue as well: epothilone B rescuing JNK-P.

Important points that should be addressed:

1\) RNAi experiments The authors present no phenotypes after 18 DIV using RNAi, but then at 26DIV \-- again only Syt punctae as read-out -- what is the overall morphology of these neurons. It is unclear what is happening to these cells from pictures. ato-RNAi has similar problems -- in both cases it is unclear when neurons are actually running out of protein, and it is unclear whether there is a developmental defect or no rescue... These \'delay experiment\' does not allow to conclude \'not only required for development, but also maintenance\'.

2\) kinesin and drug experiments. The kinesin (unc104) overexpression rescue of the shot, tau double mutant is a strong experiment. The authors show rescue of syt puncta at 2 DIV. As above, we are not sure what the overall morphology and issues of these cells are. Are these really fully rescued neurons? Unfortunately there is no in vivo experiment in this case. How about brp? Does it also rescue the \'aging/maintenance\' issues?

The authors find that the microtubule-stabilizing drug epothilone B also provides a significant rescue of Syt \'intensity\' in cultured neurons at DIV 2. Like the puncta graphs, everything is normalized to 100 in the graph (6E), but apparently now intensity and not numbers of puncta are compared? Why? Next the authors produce microtubule stress with nocodazole and report active JNK redistribution similar to the tau, shot double mutant and conclude that microtubule stress is the underlying cause. The key test of this idea would be epothilone B treatment to reduce microtubule stress and show that JNK-P is normalized, but unfortunately this experiment is missing.

3\) JNK experiments

The attenuation of the JNK pathway itself as a partial rescue of the tau, shot double mutant is again a strong experiment. However, again the selective read-outs and different experimental approaches make it difficult to come to a straight-forward conclusion. For example, in the brain the authors use a DN for bsk to attenuate JNK signaling, but the same method is not used for comparison for the syt count experiments in DIV 2 neurons. Why is n-syb used as a read-out at the end of the paper for the first time? Furthermore, there is no information how either of the JNK attenuation approaches affects Unc104 localization and function.

10.7554/eLife.14694.038

Author response

*Essential revisions:*

The abstract and introduction might be toned down a little and move away from the idea of \'homeostasis\'. This term has become all things to all folks, and \'synaptic maintenance\' or similar phrasing could be used.

We toned down the abstract and introduction and exchanged the term \'homeostasis\' for \'synaptic maintenance\' throughout the manuscript

*The authors should take time within the results to explain the experimental system -- i.e. the tau mutants are lethal, and the primary culture allows examination of neurons beyond this lethal stage.*

We have added the suggested changes in the text.

For [Figure 1](#fig1){ref-type="fig"}, we would suggest including, or referring to the later figure where double heterozygotes of shot/tau give significant data -- this more directly alludes to the pathway, rather than two loss-of-function mutants making a defective phenotype worse (But see below on this). They also refer often to \'synapses\' when a more precise description of (something like) \'materially deficient\' synapses would be useful.

Thanks for pointing this out. When discussing the issue of redundancy, we now refer to [Figure 5A](#fig5){ref-type="fig"} and indicate that double-heterozygotes give significant reduction in synapses supporting the idea that tau and shot function in the same pathway. As further proof of redundancy, we are now including cross-rescue experiments between tau and shot (Figure 1---figure supplement 3).

*The most widely used method to count presynaptic sites in Drosophila is to stain them with specific antibodies against presynaptic proteins. Accordingly, a reduction in the number of Syt- or Brp-stained puncta is commonly interpreted as reduction in the number of presynaptic sites. We used this strategy with both synaptic markers in the first part of the manuscript in order to characterise the phenotypes. For the rest of the paper we mostly focused on Syt which has been used previously to quantify presynaptic sites (see as an example Wan et al., Neuron, 2000; Liu et al., The Journal of Neuroscience 2010; Franciscovich et al., Genetics 2008 and Rieckhof et al., Journal of Biological Chemistry, 2003). We have introduced a description of the phenotype, which is more precise: "\[...\]tau-deficient primary neurons contain fewer Brp and Syt positive presynaptic specialisations. In the following, we will refer to this phenotype as "synapse reduction". We find that exchanging the term synapses by materially deficient synapses across the text would make the reading of the paper unnecessary complicated.*

The strongest experiments in the paper are the rescue of tau, shot mutants through unc104 overexpression and through JNK attenuation. However, in these cases, only selective read-outs are used (for example, we do not learn whether JNK attenuation affects unc104, as predicted by the model).

We performed new experiments both in culture and in embryos for the rescue of tau-shot mutants through JNK attenuation and stained for unc104. As the model predicts, we find that the aberrant localisation of unc104 in the somas is rescued upon JNK attenuation, and we demonstrate this both in vivo and in vitro. These data are now discussed in the results part and shown in [Figure 8 ---figure supplement 1](#fig8s1){ref-type="fig"} and [2](#fig8s2){ref-type="fig"}.

*Sometimes read-outs focus on syt punctae, sometimes brp, n-syb and different ages in culture or* in vivo*. Different read-outs in different experiments make comparisons more difficult.*

At the beginning of the results part we look at both Syt and Brp punctae in the single and double *tau-shot* mutant neurons to demonstrate that several presynaptic proteins are affected. Subsequently, we consistently focus on Syt and, in some instances n-Syb is used for technical reasons (see below). We have made sure that in the text, the use of readouts and stages are clearly indicated.

*A principal concern arising from the presentation of selective read-outs is the specificity of the phenotypes. Defective syt puncta (the most commonly used read-out in the paper) can arise directly and indirectly from numerous causes. Just because they become more when there is more kinesin does not mean that the function of tau and shot is truly rescued.*

We provide many data that point to the involvement of kinesin-3 and defective transport in this synaptic function. These indications include the defects in transport, the defective localisation of Unc-104 in *shot-tau* mutant neurons, the genetic interactions between *tau*, *shot* and *unc-104* and the Unc-104 rescue experiments. These experiments support our model that diminished function of Unc-104 in axons is the cause for the synaptic defects and that synaptic defects are not the consequence of general ill health of neurons. We can also rule out that defective Syt puncta is an indirect consequence of defects in axonal length and number of branches of cultured neurons since our new analyses of morphological parameters show no correlation between synaptic phenotypes and change in morphology (see also the new passage in the Discussion).

As for the ability of kinesin-3 to truly rescue the function of Tau and Shot, we only claim that kinesin-3 rescues the synaptic phenotypes in double mutant neurons. Tau and Shot are microtubule regulators and regulate other aspects of neuronal physiology and morphology, which are independent of kinesin-3.

I am wondering what these neurons look like, what other markers look like and what aspects of neuronal function and maintenance are truly \'rescued\' with unc104 overexpression compared to the microtubule-stabilizing drug compared to JNK signaling attenuation.

These data are now provided under \"Required experiments\" below.

*Finally, a key issue is the lack of simple genetic rescue experiments. The authors only provide one tau rescue experiments at the beginning of the paper. The shot mutant is never rescued by a shot transgene.*

These data are now provided, see next under \"Required experiments\".

*In sum, while we find the paper compelling and interesting substantial revisions are required and should be done within the two month period required by eLife.*

Required experiments:

1\) Rescue of shot, rescue attempt of tau with shot and rescue attempt of shot with tau. Only these experiment reveal functional overlap.

We now include a series of rescue experiments. We found a very good rescue of the synaptic phenotypes with *shot* rescue in *tau* mutants, *shot* rescue in *shot* mutants and *tau* rescue in *shot* mutants, further confirming our hypothesis of functional overlap between these proteins. These results are now incorporated in the text and the data is shown in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.

*We do not think the rescue of the double mutant with either tau or shot is as meaningful, because the double mutant clearly gets worse than any single and any single rescue in that background would make it better, without revealing functional overlap of the two proteins.*

*2) Morphology of the neurons throughout, in mutants and rescues, to show to what extent syt puncta counts are a consequence of more severe neuronal defects.*

We incorporated the analysis of axonal length and number of branches of cultured neurons. We find that in the double mutant condition, the length of axons is not significantly affected but the number of branches is reduced. We performed similar analysis for the tau-shot RNAi experiments at 3, 18 and 26 DVI. In none of the time points we observed changes in axonal length nor in branch number of tau-shot RNAi neurons when compared to control neurons. This data clearly indicates that the synaptic phenotype occurs independently of the branching phenotype.

We further quantified axonal length and branch number in the rescues of *tau-shot* with unc104 overexpression and JNK attenuation. We find that axonal length is slightly reduced in both conditions and the number of branches remains significantly reduced in the unc104 rescues but is rescued upon JNK attenuation. Therefore, there is clearly no correlation between morphological changes and changes in synapse number. These data are explained in the results and presented in [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"} and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}.

*3) Further regarding the specificity issue: Please see the reference in the review below to how the original unc104 paper made its point on specificity (mitochondria, HRP, fasII, mCD8, -- subset of these). The key is whether this is a defect specific to synaptic proteins as proposed or a general transport or even health problem of these neurons.*

Since we can successfully rescue the synaptic phenotype at the various levels of the pathological pathway (and find no correlation with morphological changes affected differently in these rescues; see previous point), we are confident that the synaptic defects we observe are dependent on and specific for the pathway we describe and not the indirect consequence of general cellular decay. As discussed above, Tau and Shot are microtubule regulators and, as such, regulate other aspects of neuronal physiology and morphology. Accordingly, we do not claim at any point that Tau and Shot function exclusively regulates the transport of synaptic proteins.

*4) The authors should use UNC-104 as a readout in the rescues and throughout for mutants presented. JNK-P is also key as presented by the authors.*

We did new rescue experiments and tested the localisation of unc104. Both in vivo and in vitro, the aberrant localisation of unc104 in the somas is rescued upon JNK attenuation, as is consistent with our model. These data are now discussed in the results part and presented in [Figure 8](#fig8){ref-type="fig"} S1 and S2. As for JNK-P we also confirmed that epothilone B rescues the localisation of JNK-Pin *tau-shot* i.e. it increases the localisation of JNK-P at axonal tips and reduces the aberrant localisation is somas ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

*5) The pharmacological experiments require some level of meaningful rescue as well: epothilone B rescuing JNK-P.*

This experiment has been performed successfully.

Important points that should be addressed:

*1) RNAi experiments The authors present no phenotypes after 18 DIV using RNAi, but then at 26DIV \-- again only Syt punctae as read-out -- what is the overall morphology of these neurons. It is unclear what is happening to these cells from pictures. ato-RNAi has similar problems -- in both cases it is unclear when neurons are actually running out of protein, and it is unclear whether there is a developmental defect or no rescue... These \'delay experiment\' does not allow to conclude \'not only required for development, but also maintenance\'.*

Detailed morphological data for RNAi experiments in cell culture have been added. In summary, at any of the time points: 3, 18 and 26 DVI we observed changes in axonal length nor in branch number of tau-shot RNAi neurons. For the ato-RNAi we use independent readouts to assess the number of axonal branches and find that precocious synapse decay is not due to axonal loss or to changes in branch patterns ([Figure 3E-F](#fig3){ref-type="fig"}).

The reviewer wonders when neurons are actually running out of protein.To clarify this, we performed experiments in primary neuronal cultures with RNAi for *tau* and *shot* and stained with anti-Shot and anti-Tau at 3 DIV and 25 DVI. We find that at 3 DIV the intensity of anti-Shot is unchanged when compared to controls. By 25 DIV the intensity of anti-Shot is down to at least 50% when considering background levels in staining that are suggested by parallel controls with null mutant neurons. As for Tau, the intensity of anti-Tau is lower than controls at 3 DIV and it continues to decrease significantly between 3 and 25 days. These results support that this strategy takes out Tau and Shot functions with some delay, overcoming developmental functions (i.e. pre-synaptic sites can be properly established as well as axonal branches). These data can be found in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.

*2) kinesin and drug experiments. The kinesin (unc104) overexpression rescue of the shot, tau double mutant is a strong experiment. The authors show rescue of syt puncta at 2 DIV. As above, we are not sure what the overall morphology and issues of these cells are. Are these really fully rescued neurons? Unfortunately there is no* in vivo *experiment in this case. How about brp? Does it also rescue the \'aging/maintenance\' issues?*

The outcome of our morphology studies of Unc104 rescue was described above and suggests that Unc104 only fully rescues the transport-related, synaptic phenotypes of the *tau-shot* double mutant neurons (now shown in [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). The involvement of Unc104 is supported by rescue experiments but is further supported by transport assays, genetic interaction between *tau-shot* and *unc104* and the substantial changes in the localisation of Unc104 (as described already in the first manuscript version).

As for the aging/maintenance issue, we now also provide unc104 brain rescues of aging/maintenance phenotypes induced by tau-shot RNAi in vivo (Figure 5---figure supplement 2).

Concerning BRP, it has been previously demonstrated that Syt and BRP are both transported by unc-104, therefore it is expected that defects in Unc104 function will affect both synaptic proteins (Pack-Chung et al., 2007). To repeat the unc-104 rescues using BRP will take more than 2 months since the fly stocks need to be re-established. We feel that the advance provided by such data is not sufficient to justify the time investment.

*The authors find that the microtubule-stabilizing drug epothilone B also provides a significant rescue of Syt \'intensity\' in cultured neurons at DIV 2. Like the puncta graphs, everything is normalized to 100 in the graph (6E), but apparently now intensity and not numbers of puncta are compared? Why?*

The experiments with epothilone B are not performed in cultured neurons but in embryonic motoraxons. The terminal of these axons at this developmental stage is very narrow and small; it is not possible to quantify separated puncta. To overcome this caveat, we quantified the intensity of synaptotagmin staining as we did similarly in [Figure 2B](#fig2){ref-type="fig"}.

*Next the authors produce microtubule stress with nocodazole and report active JNK redistribution similar to the tau, shot double mutant and conclude that microtubule stress is the underlying cause. The key test of this idea would be epothilone B treatment to reduce microtubule stress and show that JNK-P is normalized, but unfortunately this experiment is missing.*

We now show that epothilone B treatment normalises JNK-P, these data are presented in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.

*3) JNK experiments*

The attenuation of the JNK pathway itself as a partial rescue of the tau, shot double mutant is again a strong experiment. However, again the selective read-outs and different experimental approaches make it difficult to come to a straight-forward conclusion. For example, in the brain the authors use a DN for bsk to attenuate JNK signaling, but the same method is not used for comparison for the syt count experiments in DIV 2 neurons. Why is n-syb used as a read-out at the end of the paper for the first time?

The JNK pathway can be attenuated in different ways, for example using mutations in *wnd*, expressing UAS-puc and Uas-bsk-DN. All these methods have been frequently used by others and are widely accepted. Our choice of method was for technical reasons. For culture studies, the *wnd* mutation and UAS-puc could be easier combined with the *tau-shot* mutant chromosome. For in vivo studies in the adult brain, the X-chromosomal Uas-bskDN was easier to combine with the existing Uas-tau-RNAi, Uas-shot-RNAi, ato-Gal4 and Uas-nSyb fly lines. Similarly, for technical reasons, we used nSyb instead of Syt in a few experiments in the adult brain. The reduction in nSyb we observed can be taken as a further confirmation for the phenotype described for Syt and is in agreement with previous reports demonstrating that nSyb is also transported by Unc-104 (Pack-Chung et al., 2007).

*Furthermore, there is no information how either of the JNK attenuation approaches affects Unc104 localization and function.*

We performed new experiments showing that JNK attenuation restores Unc104 to normal distribution patterns. We present these data in [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} and [2](#fig8s2){ref-type="fig"}.
